Low-Dose Aspirin Label Could Pose High Commercial Hurdle For Brilinta
Executive Summary
AstraZeneca could face a significant commercial challenge for its antiplatelet agent Brilinta (ticagrelor) if, as expected, FDA approves the drug with a recommendation for concomitant use of low-dose aspirin in acute coronary syndrome patients
You may also be interested in...
Brilinta Approval Shows AstraZeneca's Success With Aspirin Theory, But Can It Change The Market?
FDA appears to have come around to the "aspirin hypothesis" offered by AstraZeneca PLC to explain poor results for North American patients who took the blood-thinner Brilinta, though labeling takes a somewhat cautious approach that reflects initial concerns about that explanation.
Brilinta Approval Shows AstraZeneca's Success With Aspirin Theory, But Can It Change The Market?
FDA appears to have come around to the "aspirin hypothesis" offered by AstraZeneca PLC to explain poor results for North American patients who took the blood-thinner Brilinta, though labeling takes a somewhat cautious approach that reflects initial concerns about that explanation.
Brilinta "Complete Response" Letter Suggests FDA Unswayed On U.S. Efficacy
Agency asks AstraZeneca for additional analyses of data from the 18,000-patient PLATO study, in which no benefit of ticagrelor over clopidogrel was seen in U.S. acute coronary syndrome patients.